| |
Abbott's New HCV Study: ABT450+ABT072+Ribavirin
|
| |
| |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
This study is currently recruiting participants.
Verified by Abbott, October 2010
Official Title: An Open Label Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) in Treatment-Na•ve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
| |
| |
| |
|
|
|
